Biopharmaceutical company Clovis Oncology, Inc. announces pricing of its $130 million initial public offering.
On November 15, Willkie client Clovis Oncology, Inc. announced the pricing of its initial public offering of 10 million shares at an initial price to the public of $13 per share, an aggregate transaction value of $130 million. The common stock will trade on the NASDAQ Global Select Market under the symbol "CLVS."
Boulder, Colorado-based Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and other international markets. Clovis Oncology targets its development programs for the treatment of specific subsets of cancer populations, and seeks to simultaneously develop, with partners, companion diagnostics that direct its product candidates to the patients that are most likely to benefit from their use. Founded in 2009, the company has three potential drugs under development, including possible treatments for metastatic pancreatic cancer, non-small cell lung cancer and various solid tumors.
The IPO was handled by William Gump, Peter Jakes, Martin Miller, Thomas Mark, Amanda Burke and Jordan Messinger.